The POLR2C antibody targets the RNA Polymerase II Subunit C (POLR2C), a critical component of the RNA polymerase II (Pol II) enzyme, which is essential for eukaryotic transcription. POLR2C, also known as RPB3. forms part of the core structure of Pol II, interacting with other subunits like RPB1 and RPB2 to stabilize the enzyme complex and facilitate its assembly. As a central player in gene expression, Pol II catalyzes the synthesis of messenger RNA (mRNA) by transcribing DNA into pre-mRNA, a process requiring precise regulation. POLR2C antibodies are widely used in research to study Pol II’s role in transcription initiation, elongation, and termination, as well as its interaction with transcription factors and coactivators.
These antibodies are valuable tools in techniques such as chromatin immunoprecipitation (ChIP), Western blotting, and immunofluorescence to detect POLR2C expression, localization, and post-translational modifications. Dysregulation of POLR2C has been implicated in various diseases, including cancers and neurodegenerative disorders, due to its role in maintaining transcriptional fidelity. For example, altered POLR2C levels may disrupt cellular proliferation or stress responses, contributing to tumorigenesis. Additionally, POLR2C antibodies aid in exploring Pol II pausing, promoter-proximal dynamics, and the impact of mutations on transcriptional machinery. Their application extends to drug development, particularly in targeting transcription-related pathways for therapeutic intervention. Overall, POLR2C antibodies provide crucial insights into transcriptional regulation and disease mechanisms.